MX2016017097A - Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2). - Google Patents

Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).

Info

Publication number
MX2016017097A
MX2016017097A MX2016017097A MX2016017097A MX2016017097A MX 2016017097 A MX2016017097 A MX 2016017097A MX 2016017097 A MX2016017097 A MX 2016017097A MX 2016017097 A MX2016017097 A MX 2016017097A MX 2016017097 A MX2016017097 A MX 2016017097A
Authority
MX
Mexico
Prior art keywords
cancer
biomarkers
ezh2
bapl
biomarker
Prior art date
Application number
MX2016017097A
Other languages
English (en)
Inventor
LEVINE Ross
LAFAVE Lindsay
Abdel-Wahab Omar
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2016017097A publication Critical patent/MX2016017097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La materia actualmente revelada se refiere al uso de uno o más biomarcadores para evaluar la probabilidad de que un inhibidor de EZH2 pudiera producir un efecto anticáncer en un sujeto; se basa, al menos en parte, en el descubrimiento de que la pérdida de BAP1 resulta en la sobre-regulación de la expresión y actividad de EZH2; en una modalidad específica no limitante, el método comprende obtener una muestra del cáncer de un sujeto, y determinar, en la muestra, el nivel de expresión de un biomarcador de BAP1, donde si el biomarcador de BAP1 está ausente o se expresa a un nivel menor en el cáncer en comparación con un nivel de control de referencia, entonces se administra una cantidad terapéuticamente eficaz de un inhibidor de EZH2 para producir un efecto anticáncer.
MX2016017097A 2014-06-19 2015-06-19 Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2). MX2016017097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19
PCT/US2015/036677 WO2015196064A1 (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Publications (1)

Publication Number Publication Date
MX2016017097A true MX2016017097A (es) 2017-05-01

Family

ID=54936135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017097A MX2016017097A (es) 2014-06-19 2015-06-19 Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).

Country Status (15)

Country Link
US (1) US20170138946A1 (es)
EP (1) EP3158086B1 (es)
JP (1) JP6684230B2 (es)
KR (1) KR20170020463A (es)
CN (1) CN106795561B (es)
AU (1) AU2015276899B2 (es)
BR (1) BR112016029911A2 (es)
CA (1) CA2952285A1 (es)
EA (1) EA036889B1 (es)
ES (1) ES2870096T3 (es)
IL (1) IL249443B (es)
MX (1) MX2016017097A (es)
SG (2) SG10202007972SA (es)
WO (1) WO2015196064A1 (es)
ZA (1) ZA201608555B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
JP7336193B2 (ja) * 2016-02-16 2023-08-31 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 原発性胃腺癌の体細胞プロモーター特性を明らかにするエピゲノムプロファイリング
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1992010588A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2001055454A1 (en) 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
US20030077616A1 (en) 2001-04-19 2003-04-24 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
IL159015A0 (en) 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
IL160324A0 (en) 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
AU2003239152A1 (en) 2002-04-23 2003-11-10 Millipore Corporation Sample preparation of biological fluids for proteomic applications
DK2500439T4 (da) 2005-06-20 2017-11-13 Advanced Cell Diagnostics Inc Kits og produkter til detektering af nukleinsyrer i individuelle celler og til identifikation af sjældne celler fra store heterogene cellepopulationer
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
KR102061353B1 (ko) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2012364924A1 (en) * 2011-02-16 2013-09-12 Medical University Of Graz BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
EP2825161B1 (en) 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака

Also Published As

Publication number Publication date
ZA201608555B (en) 2022-05-25
IL249443A0 (en) 2017-02-28
US20170138946A1 (en) 2017-05-18
EP3158086A4 (en) 2018-01-10
EA036889B1 (ru) 2021-01-12
KR20170020463A (ko) 2017-02-22
BR112016029911A2 (pt) 2017-10-24
SG10202007972SA (en) 2020-10-29
CN106795561B (zh) 2021-04-16
AU2015276899B2 (en) 2021-08-12
IL249443B (en) 2022-05-01
EA201692497A1 (ru) 2017-06-30
EP3158086B1 (en) 2021-03-24
JP2017525337A (ja) 2017-09-07
JP6684230B2 (ja) 2020-04-22
SG11201610610YA (en) 2017-01-27
CA2952285A1 (en) 2015-12-23
EP3158086A1 (en) 2017-04-26
AU2015276899A1 (en) 2017-01-05
ES2870096T3 (es) 2021-10-26
WO2015196064A1 (en) 2015-12-23
CN106795561A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2016017097A (es) Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).
IL259787A (en) Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
SG11201607448PA (en) Determining cancer agressiveness, prognosis and responsiveness to treatment
MX2017003637A (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EA201790802A1 (ru) Соединения против tnf
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
CL2016002419A1 (es) Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201401201A1 (ru) Способ
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
MX2016009450A (es) Ensayo novedoso para detectar periostina humana.
WO2016100745A3 (en) Methods and compositions related to transplant-associated thrombotic microangiopathy
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent